Severe Eosinophilic Asthma

Drug	Drug Name	Drug Description
DB12023	Benralizumab	A monoclonal antibody used to treat severe eosinophilic asthma.
DB06612	Mepolizumab	A fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
DB06602	Reslizumab	An IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.

Drug	Drug Name	Target	Type
DB12023	Benralizumab	Interleukin-5 receptor subunit alpha	target
DB12023	Benralizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
DB06612	Mepolizumab	Interleukin-5	target
DB06602	Reslizumab	Interleukin-5	target

Drug	Drug Name	Phase	Status	Count
DB06612	Mepolizumab	Not Available	Recruiting	1
DB06612	Mepolizumab	Not Available	Unknown Status	1
DB11900	OC-459	2	Completed	1
DB12023	Benralizumab	3	Recruiting	1
DB01001	Albuterol	4	Completed	1
DB12023	Benralizumab	4	Completed	1
DB12023	Benralizumab	4	Unknown Status	1
DB01222	Budesonide	4	Completed	1
DB00983	Formoterol	4	Completed	1